Tag Archives: EU approves drug for pancreatic cancer

AstraZeneca and Merck said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer. The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo. Lynparza, which can now be used …

Read More »